Sulfobetaine (dimethylsulfoniopropionate) and glycine betaine show incompatible involvement in crucial ehrlich ascites carcinoma in mice

Kenji Nakajima, Yoshiki Nakajima, Satomi Tsujiwaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aim: The role of methylation reactions in cancer was examined using the methylating agents, sulfobetaine [dimethylsulfonioproponate (DMSP)], and glycine betaine (GB), in murine crucial Ehrlich ascites carcinoma (EAC) for up to 10 days. Results: DMSP administration in EAC-bearing mice mitigated EAC, while GB administration clearly promoted EAC. However, the immune cell profiles did not differ largely between animals receiving DMSP and those receiving GB. Moreover, DMSP and GB had merely any effects on proliferation of EAC cells in vitro. Injection of DMSP into normal mice interestingly led to macrophage accumulation in the peritoneal cavity in a dose-dependent manner at early rearing. Conclusion: These results indicate that GB promoted EAC by the methylation of cancer promotor gene, whereas DMSP ameliorated EAC by the accumulation of activated macrophages with a rapid response and long life span during cancer progression.

Original languageEnglish
Pages (from-to)1475-1480
Number of pages6
JournalAnticancer research
Volume35
Issue number3
Publication statusPublished - Mar 1 2015

Fingerprint

Betaine
Ascites
Carcinoma
Methylation
Macrophages
Neoplasm Genes
Peritoneal Cavity
dimethylpropiothetin
sulfobetaine
Neoplasms
Injections

Keywords

  • Activated macrophages
  • Betaine
  • Dimethylsulfoniopropionate
  • Ehrlich ascites carcinoma
  • Methylation reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sulfobetaine (dimethylsulfoniopropionate) and glycine betaine show incompatible involvement in crucial ehrlich ascites carcinoma in mice. / Nakajima, Kenji; Nakajima, Yoshiki; Tsujiwaki, Satomi.

In: Anticancer research, Vol. 35, No. 3, 01.03.2015, p. 1475-1480.

Research output: Contribution to journalArticle

@article{0f90d925e62d48208675b8a6f3b937ba,
title = "Sulfobetaine (dimethylsulfoniopropionate) and glycine betaine show incompatible involvement in crucial ehrlich ascites carcinoma in mice",
abstract = "Background/Aim: The role of methylation reactions in cancer was examined using the methylating agents, sulfobetaine [dimethylsulfonioproponate (DMSP)], and glycine betaine (GB), in murine crucial Ehrlich ascites carcinoma (EAC) for up to 10 days. Results: DMSP administration in EAC-bearing mice mitigated EAC, while GB administration clearly promoted EAC. However, the immune cell profiles did not differ largely between animals receiving DMSP and those receiving GB. Moreover, DMSP and GB had merely any effects on proliferation of EAC cells in vitro. Injection of DMSP into normal mice interestingly led to macrophage accumulation in the peritoneal cavity in a dose-dependent manner at early rearing. Conclusion: These results indicate that GB promoted EAC by the methylation of cancer promotor gene, whereas DMSP ameliorated EAC by the accumulation of activated macrophages with a rapid response and long life span during cancer progression.",
keywords = "Activated macrophages, Betaine, Dimethylsulfoniopropionate, Ehrlich ascites carcinoma, Methylation reaction",
author = "Kenji Nakajima and Yoshiki Nakajima and Satomi Tsujiwaki",
year = "2015",
month = "3",
day = "1",
language = "English",
volume = "35",
pages = "1475--1480",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Sulfobetaine (dimethylsulfoniopropionate) and glycine betaine show incompatible involvement in crucial ehrlich ascites carcinoma in mice

AU - Nakajima, Kenji

AU - Nakajima, Yoshiki

AU - Tsujiwaki, Satomi

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background/Aim: The role of methylation reactions in cancer was examined using the methylating agents, sulfobetaine [dimethylsulfonioproponate (DMSP)], and glycine betaine (GB), in murine crucial Ehrlich ascites carcinoma (EAC) for up to 10 days. Results: DMSP administration in EAC-bearing mice mitigated EAC, while GB administration clearly promoted EAC. However, the immune cell profiles did not differ largely between animals receiving DMSP and those receiving GB. Moreover, DMSP and GB had merely any effects on proliferation of EAC cells in vitro. Injection of DMSP into normal mice interestingly led to macrophage accumulation in the peritoneal cavity in a dose-dependent manner at early rearing. Conclusion: These results indicate that GB promoted EAC by the methylation of cancer promotor gene, whereas DMSP ameliorated EAC by the accumulation of activated macrophages with a rapid response and long life span during cancer progression.

AB - Background/Aim: The role of methylation reactions in cancer was examined using the methylating agents, sulfobetaine [dimethylsulfonioproponate (DMSP)], and glycine betaine (GB), in murine crucial Ehrlich ascites carcinoma (EAC) for up to 10 days. Results: DMSP administration in EAC-bearing mice mitigated EAC, while GB administration clearly promoted EAC. However, the immune cell profiles did not differ largely between animals receiving DMSP and those receiving GB. Moreover, DMSP and GB had merely any effects on proliferation of EAC cells in vitro. Injection of DMSP into normal mice interestingly led to macrophage accumulation in the peritoneal cavity in a dose-dependent manner at early rearing. Conclusion: These results indicate that GB promoted EAC by the methylation of cancer promotor gene, whereas DMSP ameliorated EAC by the accumulation of activated macrophages with a rapid response and long life span during cancer progression.

KW - Activated macrophages

KW - Betaine

KW - Dimethylsulfoniopropionate

KW - Ehrlich ascites carcinoma

KW - Methylation reaction

UR - http://www.scopus.com/inward/record.url?scp=84924973831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924973831&partnerID=8YFLogxK

M3 - Article

C2 - 25750300

AN - SCOPUS:84924973831

VL - 35

SP - 1475

EP - 1480

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -